HealthQuill AstraZeneca
British-Swedish AstraZeneca signed a $1.92 billion licensing agreement with CSPC Pharmaceutical Group to develop, manufacture and commercialize a compound to treat a metabolic disorder.
Drugs Health Medical

AstraZeneca in $1.92 million deal with HK-listed CSPC Pharmaceutical

British-Swedish AstraZeneca signed a $1.92 billion licensing agreement with CSPC Pharmaceutical Group to develop, manufacture and commercialize a compound to treat a metabolic.

Read More
British-Swedish AstraZeneca’s drug for treatment of a form of blood cancer has been granted a Priority Review in the US by the drug regulator.
Drugs Health Pharma

AstraZeneca’s experimental blood cancer drug gets US priority review

British-Swedish AstraZeneca’s drug for treatment of a form of blood cancer has been granted a Priority Review in the US by the drug.

Read More
AstraZeneca’s Flumist, the first at-home flu vaccine, got approved by the Food and Drug Administration, enabling consumers with a prescription to order online beginning next year.
Drugs Medical Pharma

US drug regulator approves first nasal spray to prevent influenza

HQ Team September 22, 2024: AstraZeneca’s Flumist, the first at-home flu vaccine, got approved by the Food and Drug Administration, enabling consumers with.

Read More
Daiichi Sankyo and AstraZeneca’s breast cancer treatment ran into opposition from the UK’s healthcare spending watchdog, which wants Enhertu drug to be offered at a “fair price.”
Drugs Health Pharma

UK watchdog blocks AstraZeneca, Daiichi’s breast cancer drug

Daiichi Sankyo and AstraZeneca’s breast cancer treatment ran into opposition from the UK’s healthcare spending watchdog, which wants Enhertu drug to be offered.

Read More
British-Swedish AstraZeneca has acquired Amolyt Pharma for $1.05 billion to gain access to Lyon, France-based company’s rare disease, late-stage pipeline.
Drugs Health Pharma

AstraZeneca acquires France’s Amolyt Pharma for $1.05 billion

British-Swedish AstraZeneca has acquired Amolyt Pharma for $1.05 billion to gain access to Lyon, France-based company’s rare disease, late-stage pipeline.

Read More
The Europen Union has approved AstraZeneca’s Tagrisso along with chemotherapy treatment for lung cancer patients after trials showed an extended nine months of survival.
Drugs Health Pharma

AstraZeneca’s medicine for non-small lung cancer gets EU nod

HQ Team July 5, 2024: The Europen Union has approved AstraZeneca’s Tagrisso along with chemotherapy treatment for lung cancer patients after trials showed.

Read More
AstraZeneca’s end-stage experimental trial to treat a certain type of breast cancer failed to meet its dual primary goals, according to a statement.
Drugs Health Pharma

AstraZeneca’s trial breast cancer drug fails to meet primary goals

AstraZeneca’s end-stage experimental trial to treat a certain type of breast cancer failed to meet its dual primary goals, according to a statement.

Read More
The US Food and Drug Administration has approved AstraZeneca’s combination therapy, Imfinzi, for adult patients with endometrial cancer, according to a company statement.
Drugs Health Pharma

FDA gives nod for AstraZeneca’s Imfinzi to treat endometrial cancer

The US Food and Drug Administration has approved AstraZeneca’s combination therapy, Imfinzi, for adult patients with endometrial cancer, according to a company statement.

Read More
AstraZeneca’s mantle cell lymphoma combination rug, Calquence, reduced the risk of disease progression or death by up to 27%, according to a company statement.
Drugs Health Pharma

AstraZeneca’s trial drug for mantle cell lymphoma raises survival rate

AstraZeneca’s mantle cell lymphoma combination rug, Calquence, reduced the risk of disease progression or death by up to 27%, according to a company.

Read More
AstraZeneca’s oral drug to treat type-2 diabetes in patients aged 10 years and above has got approval from the US drug regulator, according to a company statement.
Drugs Health Pharma

FDA approves AstraZeneca’s type-2 diabetes drug in US market

AstraZeneca’s oral drug to treat type-2 diabetes in patients aged 10 years and above has got approval from the US drug regulator, according.

Read More